Ƶ

Vitamin D-MS Link; Nootropic Gummies Laced With Psilocybin; Forecasting Seizures

— News and commentary from the world of neurology and neuroscience

Ƶ MedicalToday
NeuroBreak over a computer rendering of neurons.

before starting treatment were tied to subsequent multiple sclerosis (MS) disease activity. (Journal of Neurology, Neurosurgery, and Psychiatry)

Several brands of , marketed to enhance cognitive function, contained undisclosed psilocybin and psilocin. (Morbidity and Mortality Weekly Report)

Researchers showed how and changed communication pathways connecting brain regions. (Nature)

Two top officials at Cassava Sciences resigned after a federal grand jury filed fraud charges against a research collaborator. The company's , simufilam, is in phase III trials. (New York Times)

Researchers launched a new from the A4 study of pre-symptomatic Alzheimer's disease, the Keck School of Medicine of USC said.

Ofatumumab (Kesimpta) was more effective than teriflunomide (Aubagio) at helping reach three-parameter no evidence of disease activity (NEDA-3), a post hoc analysis showed. (Neurology)

Functional connectivity of hippocampal networks could . (Nature Medicine)

Uninsured and Hispanic people were less likely to be referred to in 2017-2018, National Inpatient Sample data showed. (Neurology Clinical Practice)

A machine-learning model identified , each with distinct progression patterns. (NPJ Digital Medicine)

  • Judy George covers neurology and neuroscience news for Ƶ, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.